Veracyte, Inc. Cash Flow Statement
VCYT / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Veracyte, Inc. generated $136M in operating cash flow and $127M in free cash flow in FY2025. Free cash flow margin was 24.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $66.4M | $24.1M | -$74.4M | -$36.6M | -$75.6M | -$34.9M | -$12.6M | -$23.0M | - | - | - | - | - | - | - |
| Depreciation & Amortization | $21.4M | $23.5M | $27.2M | $25.9M | $19.6M | $7.9M | $4.1M | $3.9M | $3.8M | $3.5M | $2.3M | $1.2M | $999.0K | $706.0K | $611.0K |
| Operating Cash Flow | $136.3M | $75.1M | $44.2M | $7.5M | -$31.6M | -$9.7M | -$3.2M | -$13.5M | -$23.9M | -$28.0M | -$27.0M | -$27.6M | -$19.2M | -$7.2M | -$13.5M |
| Capital Expenditures | $9.7M | $11.3M | $10.0M | $8.5M | $5.4M | $2.8M | $2.8M | $1.9M | $1.8M | $4.2M | $6.2M | $2.0M | $1.3M | $1.5M | $276.0K |
| Free Cash Flow | $126.6M | $63.8M | $34.3M | -$1.0M | -$37.0M | -$12.5M | -$6.0M | -$15.4M | -$25.7M | -$32.2M | -$33.1M | -$29.7M | -$20.5M | -$8.6M | -$13.8M |
| FCF Margin | 24.5% | 14.3% | 9.5% | -0.3% | -16.9% | -10.7% | -5.0% | -16.7% | -35.7% | -49.5% | -66.9% | -77.6% | -93.6% | - | - |